Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors

被引：392

作者：

Sabbah, Dima A. ^{[1
]}

Hajjo, Rima ^{[1
]}

Sweidan, Kamal ^{[2
]}

机构：

[1] Al Zaytoonah Univ Jordan, Fac Pharm, Dept Pharm, POB 130, Amman 11733, Jordan

[2] Univ Jordan, Dept Chem, Amman 11942, Jordan

来源：

CURRENT TOPICS IN MEDICINAL CHEMISTRY | 2020年 / 20卷 / 10期

关键词：

EGFR; HER-1; ERBB-1; Tyrosine kinase; EGF; TGF-alpha; mAbs; Inhibitors; cancer; TYROSINE KINASE INHIBITORS; HUMAN CANCER-CELLS; PHASE-I SAFETY; MONOCLONAL-ANTIBODY; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; FACTOR-ALPHA; LUNG-CANCER; ANTITUMOR-ACTIVITY; LIGAND-BINDING;

D O I：

10.2174/1568026620666200303123102

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The epidermal growth factor receptor (EGFR) belongs to the ERBB family of tyrosine kinase receptors. EGFR signaling cascade is a key regulator in cell proliferation, differentiation, division, survival, and cancer development. In this review, the EGFR structure and its mutations, signaling pathway, ligand binding and EGFR dimerization, EGF/EGFR interaction, and the progress in the development of EGFR inhibitors have been explored.

引用

页码：815 / 834

页数：20

共 50 条

[41] Investigating the Structure of Epidermal Growth Factor Receptor (EGFR) Dimers and Oligomers in Cells
Needham, Sarah R.
Iyer, Sumanth
Davis, Benjamin
Domingues, Laura Zanetti
Roberts, Selene K.
Rolfe, Daniel R.
Martin-Fernandez, Marisa
BIOPHYSICAL JOURNAL, 2021, 120 (03) : 326A - 327A
[42] Hepatotoxicity of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs)
Zhu, Lulin
Yang, Xinxin
Wu, Shanshan
Dong, Rong
Yan, Youyou
Lin, Nengming
Zhang, Bo
Tan, Biqin
DRUG METABOLISM REVIEWS, 2024, 56 (03) : 302 - 317
[43] Sulindac metabolites (SMS) inhibit epidermal growth factor receptor (EGFR) signaling and induce lysosomal/proteasomal degradation of EGFR
Pangburn, Heather A.
Rice, Pamela L.
Ahnen, Dennis
GASTROENTEROLOGY, 2008, 134 (04) : A242 - A243
[44] Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
Rashmi R. Shah
Devron R. Shah
Drug Safety, 2019, 42 : 181 - 198
[45] Discovery of Novel Epidermal Growth Factor Receptor (EGFR) Inhibitors Using Computational Approaches
Huo, Donghui
Wang, Shiyu
Kong, Yue
Qin, Zijian
Yan, Aixia
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2021, : 5149 - 5164
[46] Epidermal growth factor receptor (EGFR)-inhibitors, rashes, and survival: Is doxycycline the missing link?
Palma, David
ORAL ONCOLOGY, 2010, 46 (04) : E25 - E26
[47] The role of autocrine epidermal growth factor receptor (EGFR) signaling in breast cancer metastasis
Zhou, Zhen Ni
Kenny, Paraic
Segall, Jeffrey
Wiley, H. Steven
CANCER RESEARCH, 2012, 72
[48] Signaling pathways for lysophosphatidic acid (LPA) inhibition of epidermal growth factor receptor (EGFR) binding in lung epithelial cells
Toews, ML
Parker, SM
Kassel, KM
FASEB JOURNAL, 2006, 20 (04): : A695 - A695
[49] Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas
Magkou, Christina
Nakopoulou, Lydia
Zoubouli, Christina
Karali, Kanelina
Theohari, Irene
Bakarakos, Panagiotis
Giannopoulou, Ioanna
BREAST CANCER RESEARCH, 2008, 10 (03):
[50] Expression of Amphiregulin, Epidermal Growth Factor Receptor (EGFR) and Phosphorylated EGFR in Ampullary Carcinoma
Mikhitarian, K.
Merchant, N.
Revetta, F.
Shi, C.
LABORATORY INVESTIGATION, 2012, 92 : 447A - 447A

← 1 2 3 4 5 →